Physicians' Academy for Cardiovascular Education

Benefit of TTR-stabilizer starts as early as 3 months in transthyretin amyloid cardiomyopathy

3' education - Nov. 15, 2023 - Ahmad Masri, MD - Portland, OR, US

Educational information

This video was recorded during the AHA Scientific Sessions 2023 in Philadelphia, PA, US.


Ahmad Masri is a cardiologist at OHSU Center for Hypertrophic Cardiomyopathy and Amyloidosis in Portland, OR, US.


This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.

Read our summary of the primary analysis of the ATTRibute-CM-trial

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: